ABCL

Abcellera Biologics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 3/10
  • Value↓ 0/10
Abcellera Biologics sales and earnings growth
ABCL Growth
Neutral
  • Revenue Y/Y↑ 160.56%
  • EPS Y/Y↑ 10.91%
  • FCF Y/Y↑ 6.89%
Abcellera Biologics gross and profit margin trends
ABCL Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -194.90%
  • ROIC 5Y↓ -14.98%
Abcellera Biologics net debt vs free cash flow
ABCL Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Abcellera Biologics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗